The aryl hydrocarbon receptor (AhR) as a drug target for cancer chemotherapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The aryl hydrocarbon receptor (AhR) is overexpressed in some patients with different tumor types, and the receptor can be a negative or positive prognostic factor. There is also evidence from both in vivo and in vitro cell culture models that the AhR can exhibit tumor-specific pro-oncogenic and tumor suppressor-like functions and therefore can be treated with AhR antagonists or agonists, respectively. Successful clinical applications of AhR ligands will require the synthesis and development of selective AhR modulators (SAhRMs) with tumor-specific AhR agonist or antagonist activity, and some currently available compounds such as indole-3-carbinol and diindolylmethane-(DIM) and synthetic AhR antagonists are potential drug candidates. There is also evidence that some AhR-active pharmaceuticals, including tranilast, flutamide, hydroxytamoxifen and omeprazole or their derivatives, may be effective AhR-dependent anticancer agents for single or combination cancer chemotherapies for treatment of breast and pancreatic cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poland, A., & Knutson, J. C. (1982) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.22.040182.002505 · Cited by 2,515
Poland, A., Glover, E., & Kende, A. S. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33205-2 · Cited by 1,370 · cited 1×
“In contrast, clinical applications of drugs targeting AhR have been sadly lacking and this is primarily due to the fact that among all receptors, the AhR was initially identified as the receptor that bound and mediated the toxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related halogenated aromatic (HA…”
BackgroundDenison, M. S., Soshilov, A. A., He, G., DeGroot, D. E., & Zhao, B. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr218 · Cited by 748
Aoki, Y. (2001) · Environmental Research · doi:10.1006/enrs.2001.4244 · Cited by 231
Soshilov, A. A., & Denison, M. S. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01183-13 · Cited by 128
Cited by
Benzo[a]pyrene—Environmental Occurrence, Human Exposure, and Mechanisms of Toxicity
Bukowska, B., Mokra, K., & Michałowicz, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116348 · Cited by 470
Cryo-EM structure of the agonist-bound Hsp90-XAP2-AHR cytosolic complex
Gruszczyk, J., Grandvuillemin, L., Lai-Kee-Him, J., Paloni, M., Savva, C. G., Germain, P., Grimaldi, M., Boulahtouf, A., Kwong, H.-S., Bous, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34773-w · Cited by 137
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58
In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators
Mahiout, S., Tagliabue, S. G., Nasri, A., Omoruyi, I. M., Pettersson, L., Bonati, L., & Pohjanvirta, R. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.06.010 · Cited by 19
Metadata
- Authors
- Safe, S., Cheng, Y., & Jin, U.-H.
- Venue
- Current Opinion in Toxicology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 2
- Pages
- 24-29
- ISSN
- 2468-2020 (ISSN-L)
- OpenAlex
- W2583990785
- Cited by
- 99
- References
- 5
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The aryl hydrocarbon receptor (AhR) as a drug target for cancer chemotherapy. https://app.cochat.ai/papers/10.1016/j.cotox.2017.01.012
- The paper
- Safe, S., Cheng, Y., & Jin, U.-H. (2017). The aryl hydrocarbon receptor (AhR) as a drug target for cancer chemotherapy. Current Opinion in Toxicology. https://doi.org/10.1016/j.cotox.2017.01.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.